Sunesis Pharmaceuticals, Inc. (SNSS)
-NasdaqCM | Prev Close: | 5.50 |
|---|
| Open: | N/A |
|---|
| Bid: | 4.88 x 100 |
|---|
| Ask: | 7.48 x 100 |
|---|
| 1y Target Est: | 8.82 |
|---|
| Beta: | 2.66 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.30 - 6.85 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 327,252 |
|---|
| Market Cap: | 283.85M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.84 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sunesis Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 12:30 PMat Seeking Alpha(Tue, May 21)
- SUNESIS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Sunesis to Present at Upcoming Investor ConferencesGlobeNewswire(Fri, May 10)
- Sunesis Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET todayCCBN(Thu, May 9)
- Sunesis Pharmaceuticals Earnings: Here’s Why the Stock is Up Nowat Wall St. Cheat Sheet(Thu, May 9)
- Q1 2013 Sunesis Pharmaceuticals, Inc. Earnings Release - Before Market OpenCCBN(Thu, May 9)
- Sunesis Pharmaceuticals Reports First Quarter Financial Results and Recent HighlightsGlobeNewswire(Thu, May 9)
- SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aEDGAR Online(Thu, May 9)
- Sunesis to Host Conference Call on May 9th to Discuss First Quarter Financial Results and Recent HighlightsGlobeNewswire(Thu, May 2)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, May 1)
- Sunesis to Present at the Needham & Company 12th Annual Healthcare ConferenceGlobeNewswire(Wed, Apr 24)
- SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Wed, Apr 10)
- Over $400 Million Raised by U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings in 2012, Reports Brinson PatrickPR Newswire(Mon, Apr 8)
- SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EEDGAR Online(Wed, Mar 27)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 49.43 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.81 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
View More